Becton Dickinson stock gains after strong Q3 2026 results and dividend signal

Becton, Dickinson and Company stock (ISIN US0718131099) has been trading near USD 185 on the NYSE after investors reacted positively to strong third quarter fiscal 2026 figures, including revenue of around USD 5.0 billion and adjusted EPS of USD 3.23 for the quarter ended June 30, 2026 as reported on September 15, 2026.

Q3 2026 results support the share price

According to Becton Dickinson investor relations, total BD revenue in the third quarter of fiscal 2026 reached USD 5.0 billion for the period ended June 30, 2026, up 5.4 percent year on year compared with the same quarter of the prior fiscal year.

The same Q3 2026 overview cites adjusted EPS of USD 3.23 for the quarter ended June 30, 2026, confirming that earnings per share grew solidly versus earlier quarters in the current fiscal year as management continues to focus on margin improvement and portfolio mix, which helps underpin the current valuation.

Market reaction and price levels

Price data from major stock portals show Becton Dickinson stock recently closing at around USD 185.92 on the NYSE on September 15, 2026, representing a daily gain of about 1.65 percent compared with the previous close of approximately USD 182.91, and placing the shares close to the consensus price target band around the mid USD 180s cited in recent analyst summaries.

One comparative overview states that Becton Dickinson and Co trades at about USD 185.91, up 4.53 percent over a recent measurement period, with a market capitalization near USD 50.64 billion and the stock approaching a consensus price target of roughly USD 186.38, while mixed analyst sentiment is visible with around 47 percent of ratings at buy and 50 percent at hold, which suggests that further upside will depend on continued earnings momentum and execution on strategic projects.

Earnings momentum and analyst context

As TradingView reports in a sector earnings comparison dated September 16, 2026, BD posted third quarter fiscal 2026 revenue of USD 4.98 billion, which corresponds to a 5.4 percent year on year increase, and this result exceeded analysts’ revenue expectations by around 2 percent.

The same TradingView note highlights that the stock is up about 8.8 percent since the Q3 2026 results release and currently trades near USD 185.71, with the quarter characterized as strong because BD also delivered a narrow beat against analysts’ full year EPS guidance estimates and reported EPS ahead of consensus, which reinforces the perception of solid execution in the medical supplies and devices portfolio.

Dividend payments add to the appeal

Income oriented investors can also look to BD’s cash returns, as a MarketBeat summary cited in a recent equity overview notes that Becton Dickinson declared a quarterly dividend of USD 1.05 per share to be paid on September 30, 2026 to shareholders of record on September 9, 2026, with the ex dividend date also on September 9, 2026, which translates into an annualized dividend of USD 4.20 per share and a forward dividend yield of about 2.30 percent at a share price around USD 186.

Another institutional holding report summarized by MarketBeat on September 16, 2026 also refers to this USD 1.05 per share dividend and underlines that large institutional investors are adjusting their positions in the stock, which for retail investors is a sign that professional money is continuously reassessing valuation and risk reward in light of BD’s earnings trajectory and dividend policy.

Risk factors and valuation signals

In comparative analyses, BD is often described as trading near fair value relative to consensus expectations, with one forecast page indicating a current close around USD 185.92 against a street consensus price target of approximately USD 195.67, implying potential upside of around 5 to 6 percent over the medium term if earnings and cash flows develop in line with current models, while the 24/7 Wall St rating on BDX is set at Buy as of mid September 2026.

However, while the company has beaten estimates for three consecutive quarters according to recent cross stock comparisons, some analysts maintain a hold stance and emphasize risks such as regulatory changes in medical devices, competition in diagnostics and infusion systems, and cost pressures in global healthcare systems, meaning that continued revenue growth above 5 percent year on year and sustained EPS expansion will be key in justifying valuation multiples and supporting further share price gains.

Stock level and investor takeaway

For now, Becton Dickinson stock remains supported by a combination of solid Q3 2026 revenue growth of 5.4 percent to about USD 5.0 billion, adjusted EPS of USD 3.23 for the quarter ended June 30, 2026, and a quarterly dividend of USD 1.05 per share payable on September 30, 2026, with the share price around USD 185.92 on the NYSE as of September 15, 2026 and a forward dividend yield near 2.30 percent.

More news and analyses on Becton Dickinson stock